FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Henri Drugeon

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Disorders

Physiology

Geographic Areas

France

Concepts & Ideas

Drug Administration Schedule

Co-author Network

Publications

TOP 3
Christine Lascols; Patrick Legrand; A Mérens; Roland Leclercq; L Armand-Lefevre; Henri Drugeon; M D Kitzis; C Muller-Serieys; M E Reverdy; M Roussel-Delvallez; Carole Moubareck; A Lemire; A Miara; M Gjoklaj; Claude-James Soussy
In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Christine Lascols; Patrick Legrand; A Mérens; Roland Leclercq; C Muller-Serieys; Henri Drugeon; M D Kitzis; M E Reverdy; M Roussel-Delvallez; Carole Moubareck; S Brémont; A Miara; M Gjoklaj; Claude-James Soussy
In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Pascale Bemer; Marie-Emmanuelle Juvin; G Le Gargasson; Henri Drugeon; Alain Reynaud; Stéphane Corvec
Correlation between the VITEK2 system and cefoxitin disk diffusion for the daily detection of oxacillin resistance in a large number of clinical Staphylococcus aureus isolates.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Henri Drugeon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Christine Lascols; Patrick Legrand; A Mérens; Roland Leclercq; L Armand-Lefevre; Henri Drugeon; M D Kitzis; C Muller-Serieys; M E Reverdy; M Roussel-Delvallez; Carole Moubareck; A Lemire; A Miara; M Gjoklaj; Claude-James Soussy
In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2011;30(4):475-82.
2011: Christine Lascols; Patrick Legrand; A Mérens; Roland Leclercq; C Muller-Serieys; Henri Drugeon; M D Kitzis; M E Reverdy; M Roussel-Delvallez; Carole Moubareck; S Brémont; A Miara; M Gjoklaj; Claude-James Soussy
In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
International journal of antimicrobial agents 2011;37(3):235-9.
2010: Pascale Bemer; Marie-Emmanuelle Juvin; G Le Gargasson; Henri Drugeon; Alain Reynaud; Stéphane Corvec
Correlation between the VITEK2 system and cefoxitin disk diffusion for the daily detection of oxacillin resistance in a large number of clinical Staphylococcus aureus isolates.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2010;29(6):745-7.
2008: Florent Morio; Stéphane Corvec; Nathalie Caroff; Florence Le Gallou; Henri Drugeon; Alain Reynaud
Real-time PCR assay for the detection and quantification of Legionella pneumophila in environmental water samples: utility for daily practice.
International journal of hygiene and environmental health 2008;211(3-4):403-11.
2008: Martin Desrosiers; Berrylin Ferguson; Jean-Michel Klossek; Henri Drugeon; Ralph Mösges
Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis.
Current medical research and opinion 2008;24(6):1691-702.
2008: Lulla Opatowski; Laura Temime; Emmanuelle Varon; Roland Leclercq; Roland Leclerc; Henri Drugeon; Pierre-Yves Boëlle; Didier Guillemot
Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides.
PloS one 2008;3(5):e2089.
2007: Pascale Bémer; Stéphane Corvec; C Guitton; Cécile Giraudeau; G Le Gargasson; Eric Espaze; Henri Drugeon
Biological cost of fluoroquinolone resistance in Escherichia coli implicated in polyclonal infection.
Pathologie-biologie 2007;55(6):288-91.
2007: Laurent Poirel; Stéphane Corvec; Melina Rapoport; Pauline Mugnier; Alejandro Petroni; Fernando Pasteran; Diego Faccone; Marcelo Galas; Henri Drugeon; Vincent Cattoir; patrice nordmann
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
Antimicrobial agents and chemotherapy 2007;51(6):2179-84.
2007: Stéphane Corvec; Laurent Poirel; Thierry Naas; Henri Drugeon; patrice nordmann
Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii.
Antimicrobial agents and chemotherapy 2007;51(4):1530-3.
2006: Stéphane Corvec; Nathalie Caroff; Daniel Cosano; Sandie Dauvergne; Henri Drugeon; Alain Reynaud
Increased resistance to beta-lactams in a Klebsiella pneumoniae strain: role of a deletion downstream of the Pribnow box in the blaSHV-1 promoter.
International journal of antimicrobial agents 2006;28(4):308-12.
2006: Pascale Bémer; D Boutoille; Didier Lepelletier; C Chamoux; C Guitton; Henri Drugeon
[Clinical aspects and management of patients with tuberculous meningitis. Retrospective analysis from 1994 to 2005].
Revue de pneumologie clinique 2006;62(4):223-9.
2006: Stéphane Corvec; Laurent Poirel; Jean-Winoc Decousser; Pierre Allouch; Henri Drugeon; patrice nordmann
Emergence of carbapenem-hydrolysing metallo-beta-lactamase VIM-1 in Pseudomonas aeruginosa isolates in France.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(9):941-2.
2006: Stéphanie Mendes; Pascale Bémer; Stéphane Corvec; Alexis Faure; Hervé Redon; Henri Drugeon
Cervical spondylitis due to Neisseria meningitidis.
European journal of internal medicine 2006;17(3):204-5.
2005: Christian Perronne; Henri Drugeon; P Zuck; Jamila Filipecki; N Vincent-Lacaze; Gerard Goldfarb; P Léophonte
[Efficacy and safety of extended-release clarithromycin (5-day short-course) vs telithromycin, in acute bacterial exacerbation of chronic bronchitis].
Médecine et maladies infectieuses 2005;35(10):507-15.
2005: Pascale Bémer; Marie-Emmanuelle Juvin; Stéphane Corvec; A Ros; Henri Drugeon
Correlation of agar dilution and VITEK2 system for detection of resistance to macrolides, lincosamides and pristinamycin among Staphylococcus aureus and Staphylococcus epidermidis: association with genotypes.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11(8):656-61.
2005: Didier Lepelletier; Stéphanie Perron; Philippe Bizouarn; Jocelyne Caillon; Henri Drugeon; Jean-Luc Michaud; Daniel Duveau
Surgical-site infection after cardiac surgery: incidence, microbiology, and risk factors.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2005;26(5):466-72.
2005: Stéphane Corvec; I Hazart; Alain Reynaud; G Picherot; Henri Drugeon
[Vaccination failure: case report of Haemophilus influenzae b meningitis in a 14-month-old child].
Pathologie-biologie 2005;53(2):92-6.
2005: Eric Batard; Marie-Emmanuelle Juvin; Cedric Jacqueline; Denis Bugnon; Jocelyne Caillon; Gilles Potel; Henri Drugeon
Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study.
Antimicrobial agents and chemotherapy 2005;49(1):464-6.
2004: Y Le Normand; Catherine Ganiere-Monteil; Henri Drugeon; S Abbas; M Mazeas; Marie-France Kergueris
[An example of simulation for a better understanding of PK/PD relationship of antibiotics].
Pathologie-biologie 2004;52(10):597-601.
2004: F Chabot; P Devillier; Henri Drugeon; D Dusser; Michel Fournier; J Gaillard; J M Grouin; B Housset; Gérard Huchon; P Léophonte; J F Muir; O Raffy; André-Bernard Tonnel; F Tremolieres; P Zück; valerie attali; Isabelle Boucot; J Chemali-Hudry; M Daniloski
[Prevention of COPD exacerbations: conducting a clinical trial evaluating the benefits of inhaled steroids].
Revue des maladies respiratoires 2004;21(4 Pt 1):685-8.
2004: Bernard Rouveix; François Jehl; Henri Drugeon; Ivan Brumpt; Evelyne Caulin
Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.
Antimicrobial agents and chemotherapy 2004;48(7):2394-9.
2004: A Andremont; R Cohen; Henri Drugeon
[How can antibiotics' capacity of selecting bacterial resistance be assessed].
Médecine et maladies infectieuses 2004;34 Suppl 1():S109-11.
2004: P Léophonte; C Chidiac; Henri Drugeon; S Strabach; S Cabrillac-Rives; C Chone; F Dellatolas; C Safran
[Treatment of exacerbations of chronic obstructive pulmonary disease with pristinamycin].
Revue des maladies respiratoires 2004;21(2 Pt 1):261-71.
2004: C Muller-Serieys; Henri Drugeon; Jerome Etienne; Christine Lascols; Roland Leclercq; J Nguyen; Claude-James Soussy
Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10(3):242-6.
2004: Pascale Bemer; Thomas Bodmer; Juerg Munzinger; Monique Perrin; Véronique Vincent; Henri Drugeon
Multicenter evaluation of the MB/BACT system for susceptibility testing of Mycobacterium tuberculosis.
Journal of clinical microbiology 2004;42(3):1030-4.
2004: Hedi Mammeri; Laurent Poirel; Pascale Bemer; Henri Drugeon; patrice nordmann
Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate.
Antimicrobial agents and chemotherapy 2004;48(3):716-20.
2004: Didier Lepelletier; Stéphanie Perron; Hélène Huguenin; Monique Picard; Pascale Bemer; Jocelyne Caillon; Marie-Emmanuelle Juvin; Henri Drugeon
Which strategies follow from the surveillance of multidrug-resistant bacteria to strengthen the control of their spread? A French experience.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2004;25(2):162-4.
2004: Yves le Normand; Henri Drugeon; Sarah Abbas; Brigitte Palestro
[Software modeling for better understanding of pharmacokinetic-pharmacodynamic relationships: application to azithromycin in the treatment of streptococcal tonsillitis and in acute exacerbation fo chronic bronchitis]].
Thérapie 2004;59(1):155-62.
2003: Stéphane Corvec; Nathalie Caroff; Eric Espaze; Julie Marraillac; Henri Drugeon; Alain Reynaud
Comparison of two RT-PCR methods for quantifying ampC specific transcripts in Escherichia coli strains.
FEMS microbiology letters 2003;228(2):187-91.
2003: Claude-James Soussy; J Nguyen; Fred W Goldstein; Henri Dabernat; A Andremont; Roland Leclercq; Henri Drugeon; P Cavallo; Hubert Chardon; Jerome Etienne; Yves Rio; P Courvalin
In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(10):997-1005.
2003: Didier Lepelletier; Stéphanie Perron; H Huguenin; M Picard; Pascale Bemer; Jocelyne Caillon; Marie-Emmanuelle Juvin; Henri Drugeon
[Should we screen for colonization to control the spread of multidrug resistant bacteria?].
Pathologie-biologie 2003;51(8-9):464-8.
2003: Stéphane Corvec; Nathalie Caroff; Eric Espaze; Cécile Giraudeau; Henri Drugeon; Alain Reynaud
AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains.
The Journal of antimicrobial chemotherapy 2003;52(4):629-35.
2003: Pascale Bemer; Marie-Emmanuelle Juvin; André Bryskier; Henri Drugeon
In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.
Antimicrobial agents and chemotherapy 2003;47(9):3025-9.
2002: Eric Batard; Cedric Jacqueline; David Boutoille; Antoine Hamel; Henri Drugeon; Nathalie Asseray; Roland Leclercq; Jocelyne Caillon; Gilles Potel; Denis Bugnon
Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study.
Antimicrobial agents and chemotherapy 2002;46(7):2174-8.
2002: Pascale Bemer; Sophie Leautez; Emmanuelle Ninin; Sophie Jarraud; François Raffi; Henri Drugeon
Legionella pneumophila Arthritis: use of medium specific for Mycobacteria for isolation of L. pneumophila in culture of articular fluid specimens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;35(1):E6-7.
2002: Pascale Bemer; Frantiska Palicova; Sabine Rüsch-Gerdes; Henri Drugeon; Gaby E Pfyffer
Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis.
Journal of clinical microbiology 2002;40(1):150-4.
2001: P Bemer-Melchior; Henri Drugeon
[Choice of the NaCl concentration for optimizing the detection of methicillin resistance in Staphylococcus using the gel diffusion method].
Pathologie-biologie 2001;49(3):216-21.
2000: Henri Drugeon; ML Veyries; Maryse Levacher; M Garnier; G Aymard; Jean-Paul Giroud; Bernard Rouveix
[Antibacterial activity of urine after administration of ofloxacin for 5 days].
Thérapie 2000;55(6):691-7.
2000: Claude-James Soussy; G Carret; Jean-Didier Cavallo; Hubert Chardon; C Chidiac; P Choutet; P Courvalin; Henri Dabernat; Henri Drugeon; Luc Dubreuil; Fred W Goldstein; V Jarlier; Roland Leclercq; MH Nicolas-Chanoine; Alain Philippon; C Quentin; Bernard Rouveix; Jacques Sirot
[Antibiogram Committee of the French Microbiology Society. Report 2000-2001].
Pathologie-biologie 2000;48(9):832-71.
2000: P Bemer-Melchior; Marie-Emmanuelle Juvin; S Tassin; André Bryskier; G C Schito; Henri Drugeon
In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
Antimicrobial agents and chemotherapy 2000;44(11):2999-3002.
2000: P Bemer-Melchior; André Bryskier; Henri Drugeon
Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.
The Journal of antimicrobial chemotherapy 2000;46(4):571-6.
1999: P Bemer-Melchior; A Haloun; P Riegel; Henri Drugeon
Bacteremia due to Dietzia maris in an immunocompromised patient.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(5):1338-40.
1999: P Bemer-Melchior; Henri Drugeon
Inactivation of Mycobacterium tuberculosis for DNA typing analysis.
Journal of clinical microbiology 1999;37(7):2350-1.
1999: Henri Drugeon; Marie-Emmanuelle Juvin; André Bryskier
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
The Journal of antimicrobial chemotherapy 1999;43 Suppl C():55-9.
1998: P Bemer-Melchior; P Germaud; Henri Drugeon
Diagnosis of extrapulmonary tuberculosis by a commercial polymerase chain reaction kit.
Pathologie-biologie 1998;46(8):597-603.
1998: Denis Bugnon; Gilles Potel; Jocelyne Caillon; Denis Baron; Henri Drugeon; P Feigel; Marie-France Kergueris
In vivo simulation of human pharmacokinetics in the rabbit.
Bulletin of mathematical biology 1998;60(3):545-67.
1997: Denis Bugnon; Gilles Potel; Yan-Qiong Xiong; Jocelyne Caillon; Dominique Navas; C Gras; Marie-France Kergueris; Philippe Le Conte; François Jehl; Denis Baron; Henri Drugeon
Bactericidal effect of pefloxacin and fosfomycin against Pseudomonas aeruginosa in a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivo.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1997;16(8):575-80.
1997: Yan-Qiong Xiong; Jocelyne Caillon; Marie-France Kergueris; Henri Drugeon; Denis Baron; Gilles Potel; Arnold S Bayer
Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
Antimicrobial agents and chemotherapy 1997;41(4):823-6.
1996: Yan-Qiong Xiong; Jocelyne Caillon; Henri Drugeon; Gilles Potel; Denis Baron
The effect of rifampicin on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.
The Journal of antimicrobial chemotherapy 1996;37(5):993-8.
1996: Bruno Fantin; J Pierre; N Castéla-Papin; L Saint-Julien; Henri Drugeon; Robert Farinotti; Claude Carbon
Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy 1996;40(5):1219-24.
1996: Denis Bugnon; Gilles Potel; Yan-Qiong Xiong; Jocelyne Caillon; Marie-France Kergueris; Philippe Le Conte; Denis Baron; Henri Drugeon
In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.
Antimicrobial agents and chemotherapy 1996;40(5):1164-9.
1996: Yan-Qiong Xiong; Jocelyne Caillon; Henri Drugeon; Gilles Potel; Denis Baron
Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects.
Antimicrobial agents and chemotherapy 1996;40(1):35-9.
1995: Yan-Qiong Xiong; Jocelyne Caillon; X Y Zhou; Gilles Potel; Denis Bugnon; Philippe Le Conte; F Le Gallou; R Le Floch; Denis Baron; Henri Drugeon
Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both.
The Journal of antimicrobial chemotherapy 1995;35(5):697-706.
1995: Gilles Potel; Jocelyne Caillon; Yan-Qiong Xiong; Denis Bugnon; P L Conte; Henri Drugeon; Denis Baron
[Critical serum concentration of antibiotics. A therapeutic tool and means of comparative evaluation].
Presse médicale (Paris, France : 1983) 1995;24(16):750-2.
1995: Yan-Qiong Xiong; Gilles Potel; Jocelyne Caillon; G Stephant; F Jehl; Denis Bugnon; Philippe Le Conte; Denis Baron; Henri Drugeon
Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1995;39(2):496-9.
1995: R Garraffo; Henri Drugeon
Comparative assessment of the pharmacokinetics and pharmacodynamics of ciprofloxacin after single i.v. doses of 200 and 400mg.
Drugs 1995;49 Suppl 2():317-20.
1994: Henri Drugeon; Jocelyne Caillon; M E Juvin
In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus.
The Journal of antimicrobial chemotherapy 1994;34(6):899-907.
1994: Philippe Le Conte; F Le Gallou; Gilles Potel; L Struillou; Denis Baron; Henri Drugeon
Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model.
Antimicrobial agents and chemotherapy 1994;38(12):2695-701.
1994: Y Le Normand; Henri Drugeon; Gilles Potel; Marie-France Kergueris; F Raffi; N Milpied; M C Douet; Jocelyne Caillon; J C Roźe
Teaching individualized antibiotic dosage regimens by means of two computer-assisted learning programs.
International journal of bio-medical computing 1994;36(1-2):117-9.
1994: M E Juvin; Gilles Potel; Jocelyne Caillon; Yan-Qiong Xiong; Denis Bugnon; Philippe Le Conte; D I Baron; Henri Drugeon
In vivo bactericidal activities of ciprofloxacin and pefloxacin in an experimental model of Serratia marcescens endocarditis.
Antimicrobial agents and chemotherapy 1994;38(4):883-5.
1993: Henri Drugeon; E Carpentier
[Mechanisms of adhesion of Staphylococci to biomaterials: effect of fusidic acid].
Pathologie-biologie 1993;41(4):392-8.
1992: Gilles Potel; Jocelyne Caillon; F Le Gallou; Denis Bugnon; Philippe Le Conte; J Raza; Jean-Yves Lepage; Denis Baron; Henri Drugeon
Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis.
Antimicrobial agents and chemotherapy 1992;36(4):744-50.
1991: H Etesse-Carsenti; R Garraffo; E Bernard; F de Salvador; Christian Pradier; Jacques Durant; Veronique Mondain; Henri Drugeon; Pierre Dellamonica
[Bactericidal effect of cefadroxil, amoxicillin alone or in combination with clavulanic acid in sera of healthy volunteers].
Pathologie-biologie 1991;39(10):972-7.
1991: H Etesse-Carsenti; Jocelyne Caillon; Veronique Mondain; Jacques Durant; E Bernard; Pierre Dellamonica; Henri Drugeon
[Bactericide activity of cefadroxil comparated with amoxicillin-clavulanic acid, cefaclor and josamycin].
Pathologie-biologie 1991;39(7):658-67.
1991: Gilles Potel; Jocelyne Caillon; Bruno Fantin; J Raza; F Le Gallou; Jean-Yves Lepage; Philippe Le Conte; Denis Bugnon; Denis Baron; Henri Drugeon
Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation.
Antimicrobial agents and chemotherapy 1991;35(1):111-6.
1991: Jean-Yves Lepage; Jocelyne Caillon; J M Malinowsky; S Lequerré; Antoine Cozian; Y Le Normand; Gilles Potel; Henri Drugeon; D Baron
Pharmacokinetics of norfloxacin in the elderly.
Fundamental & clinical pharmacology 1991;5(3):203-8.
1990: R Garraffo; Pierre Dellamonica; Henri Drugeon; H Etesse; P Lapalus
A new approach to optimal antibiotic dosage regimen by coupling pharmacokinetics and killing curve parameters.
Methods and findings in experimental and clinical pharmacology 1990;12(5):325-32.
1990: R Garraffo; Henri Drugeon; Pierre Dellamonica; E Bernard; P Lapalus
Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.
Antimicrobial agents and chemotherapy 1990;34(4):614-21.
1990: F Raffi; D Moinard; Henri Drugeon
Non-tuberculous mycobacterial tenosynovitis.
Lancet 1990;335(8689):613.
1989: Pierre Dellamonica; E Bernard; H Etesse; R Garraffo; Henri Drugeon
Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1989;8(12):1024-30.
1989: Jocelyne Caillon; M E Juvin; J L Pirault; Henri Drugeon
[Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against gram-positive bacteria].
Pathologie-biologie 1989;37(5 Pt 2):540-8.
1988: Henri Drugeon; Jocelyne Caillon; M E Juvin; J L Pirault
[Theoretical bases for the combination of ceftazidime with other antibiotics. Synergism research].
Presse médicale (Paris, France : 1983) 1988;17(37):1900-3.
1988: H Etesse-Carsenti; R Garraffo; F Giaume; A Barbarin; E Bernard; P Lapalus; C Argenson; Henri Drugeon; Pierre Dellamonica
[Kinetics of pefloxacin diffusion in human bone tissue following a single infusion of 800 mg. Evaluation of an extraction technic using chloroform].
Pathologie-biologie 1988;36(5 Pt 2):715-8.
1988: Gilles Potel; Jocelyne Caillon; Denis Bugnon; P Lecomte; Henri Drugeon; Denis Baron
[Experimental Enterobacter cloacae endocarditis treated with gentamicin. Predictive value of the in vitro bactericidal rate].
Pathologie-biologie 1988;36(5):536-9.
1988: Jocelyne Caillon; M E Juvin; J L Pirault; Henri Drugeon
[Kinetics of ofloxacin-amoxicillin and ofloxacin-clavulanic acid combinations against pathogenic bacteria of the respiratory tract].
Pathologie-biologie 1988;36(5):414-9.
1987: C Freland; B Massoubre; J M Horeau; Jocelyne Caillon; Henri Drugeon
Actinomycosis of the gallbladder due to Actinomyces naeslundii.
The Journal of infection 1987;15(3):251-7.
1987: C Freland; Henri Drugeon
[Campylobacter pyloridis: bacteriological study and sensitivity to antibiotics].
Pathologie-biologie 1987;35(7):1037-42.
1987: Henri Drugeon; M E Juvin; Jocelyne Caillon; A L Courtieu
Assessment of formulas for calculating critical concentration by the agar diffusion method.
Antimicrobial agents and chemotherapy 1987;31(6):870-5.
1987: C Freland; B Massoubre; Henri Drugeon
[Susceptibility of Campylobacter pyloridis to antibiotics].
Pathologie-biologie 1987;35(5 Pt 2):809-12.
1987: Gilles Potel; M Meignier; M D Touzé; G Montay; Henri Drugeon; Denis Baron
[Pharmacokinetics of pefloxacin in burn patients].
Pathologie-biologie 1987;35(5 Pt 2):777-80.
1987: Henri Drugeon; P Dellamonica; Jocelyne Caillon
[Synergy, addition, indifference, antagonism and dominance. Dominance and antibiotic combination].
Pathologie-biologie 1987;35(5):495-500.
1987: M E Juvin; Henri Drugeon; Jocelyne Caillon; J L Pirault
[Comparison of the bactericidal activity of three aminosides: gentamicin, tobramycin and amikacin].
Pathologie-biologie 1987;35(5):461-5.
1987: Henri Drugeon; Jocelyne Caillon; M E Juvin; J L Pirault
Dynamics of ceftazidime-pefloxacin interaction shown by a new killing curve-chequerboard method.
The Journal of antimicrobial chemotherapy 1987;19(2):197-203.
1986: Henri Drugeon; Jocelyne Caillon; D Moinard; M E Juvin; J L Pirault
[Bactericidal effect of piperacillin alone and combined].
Presse médicale (Paris, France : 1983) 1986;15(46):2297-302.
1986: D Moinard; P Germaud; Jocelyne Caillon; G Dabouis; Henri Drugeon
[Pulmonary cavity infection caused by Haemophilus influenzae].
Presse médicale (Paris, France : 1983) 1986;15(28):1334.
1986: A Dublanchet; Jocelyne Caillon; J-Ph Emond; H Chardon; Henri Drugeon
Isolation of Bacteroides strains with reduced sensitivity to 5-nitroimidazoles.
European journal of clinical microbiology 1986;5(3):346-7.
1986: M E Juvin; Henri Drugeon; E Bigot; Jocelyne Caillon
[Bactericidal activity of ceftriaxone, amikacin and their combination].
Pathologie-biologie 1986;34(5 Pt 2):554-8.